Serial whole-body 177Lu-SPECT quantitation for response assessment in metastatic, castration-resistant prostate cancer within a phase 1/2 trial of 177LuPSMA-617 plus NOX66 (LuPIN)
JOURNAL OF NUCLEAR MEDICINE（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要